Relay Therapeutics

Did you know, many vascular anomalies, including PIK3CA-Related Overgrowth Spectrum (PROS) and #lymphaticmalformations, are caused by mutations or changes in a single gene called PIK3CA? Genetics research continues to advance, and every new discovery helps us better understand these conditions. That's why our team was excited to attend the Annual Genetics Education Symposium: #VascularAnomalies at the @ClevelandClinic to learn from leading experts about the latest advancements in genetics and vascular anomalies. Thank you to the Cleveland Clinic team and all who contributed to a thoughtful, informative day. We’re grateful to keep learning alongside this community.

We are pleased to welcome Shannon Campbell to Relay Tx, where she will lead commercial preparations for zovegalisib in breast cancer and vascular anomalies.

Shannon has more than 30 years of experience in pharma and biotech, and has built commercial teams to launch multiple drugs. Most recently, she served as Chief Commercial Officer at Merus and prior to that, led the U.S. Solid Tumor Franchise at Novartis.

We’re thrilled to have her leadership and expertise on the team. Welcome, Shannon!

Today, we report third quarter 2026 financial results and corporate updates. We saw meaningful progress in Q3: continued Phase 3 ReDiscover-2 enrollment, now estimated to complete in mid-2027, updated ReInspire vascular anomalies data coming at #ASH26, the appointment of Shannon Campbell to lead commercial preparations for zovegalisib, and a new mutant-selective TIE2 program. Read more: ir.relaytx.com/news-releases/…

Breast cancer doesn't follow a calendar, and neither does our gratitude.

This #BreastCancerAwarenessMonth, and in every month that follows, we thank the metastatic breast cancer (MBC) community and our partners around the world.

Your knowledge, perspective, and lived experience help us understand what matters to people living with MBC, and keep our work grounded in it. Thank you.

Last weekend, the Relay Tx vascular anomalies team was in Virginia for #PeDRA2026! We were proud to present a poster on preliminary results of zovegalisib, a mutant-selective PI3Kα inhibitor, in adult and adolescent patients with PIK3CA-driven vascular malformations. Conversations throughout the conference continued to emphasize the urgency of advancing targeted options for this patient population, and we’re grateful to the PeDRA community for the opportunity to share our work and connect with others working to move this field forward.